Yahoo! FinanceFinance Home - My Yahoo - Yahoo! - Help 

Tuesday, December 29, 2009, 8:22AM ET - U.S. Markets open in 1 hour and 8 minutes. Dow Up 0.26% Nasdaq  0.00%
RXi Pharmaceuticals Corporation (RXII)On Dec 28: 4.31   0.00 (0.00%)  
MORE ON RXII
Quotes
Charts
News & Info
Company
HereProfile
Analyst Coverage
Ownership
Financials

ProfileGet Profile for:
RXi Pharmaceuticals Corporation
60 Prescott Street
Worcester, MA 01605
United States - Map
Phone: 508-767-3861
Fax: 508-767-3862
Web Site: http://www.rxipharma.com

DETAILS 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:25

BUSINESS SUMMARY 
RXi Pharmaceuticals Corporation, a discovery-stage biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on RNA interference for the treatment of human diseases in the United States and internationally. It intends to identify lead compounds and advance towards pre-clinical and clinical development programs in various therapeutic areas, including inflammatory disease; and metabolic diseases, such as obesity and obesity-related type 2 diabetes. The company was formerly known as Argonaut Pharmaceuticals, Inc. and changed its name to RXi Pharmaceuticals Corporation in 2006 before beginning operations in 2007. RXi Pharmaceuticals was founded in 2003 and is based in Worcester, Massachusetts.
Key Statistics

COMPANY WEBSITES 
  • Home Page
  • Search Yahoo! for:
    More on RXi Pharmaceuticals Corporation


    CORPORATE GOVERNANCE 
    RXi Pharmaceuticals Corporation's Corporate Governance Quotient (CGQ®) as of 1-Dec-09 is better than 68% of CGQ Universe companies and 43.4% of Pharmaceuticals, Biotechnology & Life Sciences companies.
    Brought to you by Institutional Shareholder Services.

    KEY EXECUTIVES 
     PayExercised
    Dr. Tod Woolf Ph.D., 44
    Founder and Member of the Scientific Advisory Board
    $ 330.00KN/A
    Mr. Steven A. Kriegsman , 66
    Director, Chairman of Strategy Committee, Chief Exec. Officer of CytRx and Pres of CytRx
    $ 68.00KN/A
    Dr. Pamela A. Pavco Ph.D, 53
    VP of Pharmaceutical Devel.
    $ 240.00KN/A
    Mr. Noah D. Beerman , 47
    Chief Exec. Officer and Pres
    N/A N/A
    Dr. Craig C. Mello Ph.D.,
    Co-Founder and Chairman of Scientific Advisory Board
    N/A N/A
    Dollar amounts are as of 31-Dec-08 and compensation values are for the last fiscal year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of options exercised during the fiscal year.
    View Insiders


    Add to My Portfolio Add to Portfolio    Set Alert Set Alert    Email to a Friend Email to a Friend
    Get Profile for Another Symbol: Symbol Lookup
    Annual ReportsSector Analysis